Elanco Animal Health (NASDAQ:ELAN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Elanco Animal Health Incorporated operates as an animal health care company. It develops, manufactures and markets products for companion and food animals. Elanco Animal Health Incorporated is based in Greenfield, United States. “

A number of other equities analysts also recently commented on ELAN. Argus started coverage on shares of Elanco Animal Health in a report on Tuesday, January 15th. They issued a “buy” rating and a $37.00 price objective for the company. UBS Group started coverage on shares of Elanco Animal Health in a report on Wednesday, January 23rd. They issued a “sell” rating and a $29.00 price objective for the company. William Blair started coverage on shares of Elanco Animal Health in a report on Monday, February 11th. They issued a “market perform” rating and a $29.71 price objective for the company. Morgan Stanley started coverage on shares of Elanco Animal Health in a report on Wednesday, March 13th. They issued an “equal weight” rating and a $34.00 price objective for the company. Finally, Bank of America raised shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 price objective for the company in a report on Monday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $33.47.

Elanco Animal Health stock opened at $32.75 on Tuesday. Elanco Animal Health has a 12 month low of $28.00 and a 12 month high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.03. The business had revenue of $731.10 million during the quarter, compared to analyst estimates of $743.40 million. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 EPS.

In related news, Director John P. Bilbrey bought 7,750 shares of the business’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $32.39 per share, for a total transaction of $251,022.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director R David Hoover bought 20,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was bought at an average price of $31.43 per share, for a total transaction of $628,600.00. The disclosure for this purchase can be found here.

A number of hedge funds have recently bought and sold shares of ELAN. BlackRock Inc. bought a new stake in Elanco Animal Health in the third quarter valued at $32,247,000. JPMorgan Chase & Co. bought a new stake in shares of Elanco Animal Health during the third quarter valued at about $38,358,000. LPL Financial LLC bought a new stake in shares of Elanco Animal Health during the third quarter valued at about $313,000. Legal & General Group Plc bought a new stake in shares of Elanco Animal Health during the third quarter valued at about $839,000. Finally, Morgan Stanley bought a new stake in shares of Elanco Animal Health during the third quarter valued at about $314,448,000.

Elanco Animal Health Company Profile

There is no company description available for Elanco Animal Health Inc

Featured Story: What defines an oversold asset?

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Elanco Animal Health (NASDAQ:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.